Your innovation and partnership is
integral to our success

By partnering with Ipsen, you will gain access to a like-minded global biopharmaceutical company with powerhouse development and commercialization teams. We are willing to take bold steps to translate your science and innovations into impactful products for patients in need. You will find that we are:

Collaborative

We believe teamwork and leveraging each other’s expertise are critical to maximizing success

Successful

We have a strong track record of success and an ambitious mission for growth

Decisive

We are a team of experienced professionals who are nimble, creative, responsive and ready to be decisive in executing transactions

Committed

We will share your passion to develop and commercialize your products around the world to address unmet medical needs

Competitive

We have achieved leadership in competitive global markets

Welcome

Ivana Magovčević-Liebisch, Ph.D., J.D. EVP, Chief Business Officer, Ipsen

Ipsen is entering an exciting new era as a leading global biopharmaceutical committed to delivering innovation for patient care with a goal of launching at least one new molecular entity or meaningful indication each year. Global partnerships are critical to achieve this transformation and have become the most important driver of our next phase of growth.

We have a strong foundation to build upon with 5,400 employees and products registered in over 100 countries with the U.S. being our fastest growing market.

Ipsen also has an outstanding partnership track record, progressing partnered products through global development and maximizing their value by expanding indications and opening new markets. We work with our partners to define a shared vision to unlock the full potential of their products, achieving mutual success for our partners and Ipsen. You will also find that our commitment, financial resources and size allow us to be flexible and creative in transactions.

If you have drug candidates that help patients with cancer and rare diseases or innovations that can build on our expertise in neurotoxins, we want to partner with you – because the patients can’t wait.

Best Regards,
Ivana

Ipsen facts

Flexible & innovative partnerships and deal structuring

Collaborations and Licenses

Exelixis

Galderma

DebioPharm

Shire

PharmaEngine

Lexicon Pharmaceuticals

Roche-Genentech

Photocure

Teijin

3B Pharmaceuticals

 

Asset Acquisitions

Onivyde® from Merrimack Pharmaceuticals

Select Sanofi EU Consumer Products

 

Company Acquisitions

Octreopharm Sciences

Syntaxin

Akkadeas Pharma

 

Strategic Investments

Arix Bioscience

 

Academic Partnerships

Harvard University

MD Anderson Cancer Center

Institute of Molecular and Cell Biology (A*STAR/Singapore)

 

Out-licensing

Rhythm Pharmaceuticals

Radius Health

Our Partnering Process

Successful partnerships start with a clear and transparent process that ultimately leads to developing common goals. We view every partnership opportunity as unique and our partnering process is customized to your asset and what you are looking for in a partnership with Ipsen. We aim to build a relationship with you through our partnering process.

In general, we begin our partnering process with you by ensuring your program is matched with a specialist in our External Innovation team with appropriate expertise for initial assessment at a non-confidential level.

If we are aligned on the key aspects pertaining to the potential of your program, its fit with Ipsen’s strategy and our mutual objectives of a partnership, we would progress our discussion under a confidentiality agreement to further our understanding of your program and partnering objectives, and your appreciation of what value Ipsen can bring as a partner. Our integrated team of experts will work closely with you to evaluate your confidential data and the potential of your program in detail. Our Global Business Development specialist will engage with you fully to explore a partnership structure that is mutually beneficial.

Our unique combination of size, scope and expertise as a global biopharmaceutical with a biotech mindset enables us to be decisive, competitive and creative in our partnering process. We conduct a transparent process and will stay fully engaged with you along the way.

If your asset or technology fits within one of our four core areas of focus as defined in our Partnering Focus section, we want to talk to you. Please contact our team or meet us at one of our upcoming events.




Strategic Alliance Management

When you partner with Ipsen, you will work with a dedicated member of our Alliance Management team with a relationship-focused and solution-based approach to partnership management

“Ipsen’s shared vision and global expertise in development, regulatory and commercial is helping us to deliver the potential benefits of cabozantinib to patients around the world.”

Michael M. Morrissey, Ph.D.,
President and Chief Executive Officer at Exelixis

“We believe this partnership has the potential to deliver a new therapeutic option to our patients. This focus on accelerating the development of efficient treatments is vital to our mission of ending cancer and to providing the very best care we can to those who need it most.”

Stephen Hahn, M.D.,
Chief Medical Executive at MD Anderson.

Upcoming events

2018 European Society for Medical Oncology (ESMO) Annual Congress

Munich, Germany – October 19, 2018